“如果汉霖今天还没得到你的关注，那是我的错。”复宏汉霖CEO朱俊的开场白带着理工科出身的直率。他用一串数字诠释这家企业的成长：过去四年，复宏汉霖为全球75万名患者提供可负担生物药，累计销售额超200亿元；6款上市药物中有4款在海外获批，触达50多个国家和地区；在美国、欧盟、中国等市场，复宏汉霖已实现“做一个成一个”的闭环。 2025年4月15日，上海，复宏汉霖用一场8小时的“创新马拉松”向世界...
Source Link“如果汉霖今天还没得到你的关注，那是我的错。”复宏汉霖CEO朱俊的开场白带着理工科出身的直率。他用一串数字诠释这家企业的成长：过去四年，复宏汉霖为全球75万名患者提供可负担生物药，累计销售额超200亿元；6款上市药物中有4款在海外获批，触达50多个国家和地区；在美国、欧盟、中国等市场，复宏汉霖已实现“做一个成一个”的闭环。 2025年4月15日，上海，复宏汉霖用一场8小时的“创新马拉松”向世界...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.